Repligen Corporation (NASDAQ:RGEN) saw a downside of -5.12% to $181.05 after subtracting -$9.76 on Tuesday. The 5-day average trading volume is 429,149 shares of the company’s common stock. It has gained $195.40 in the past week and touched a new high 1 time within the past 5 days. An average of 487,102 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 577,533.
RGEN’s 1-month performance is 16.36% or $13.22 on its low of $147.53 reached on 01/06/23. The company’s shares have touched a 52-week low of $137.21 and high of $262.26, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, RGEN has achieved 12.70% or $11.45 and has reached a new high 5 times. However, the current price is down -30.97% from the 52-week high price.
RGEN stock investors last saw insider trading activity on Nov 11.Hunt Anthony (Chief Executive Officer) most recently sold 25,000 shares at $200.00 per share on Nov 11. This transaction cost the insider $5,000,000. Director, DAWES KAREN A, sold 775 shares at a price of $227.17 on Sep 09. Then, on Sep 08, Chief Executive Officer Hunt Anthony sold 26,402 shares at a price of $224.73 per share. This transaction amounted to $5,933,438.
RGEN stock has a beta of 1.08. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 13.07 while the price-to-book (PB) in the most recent quarter is 5.77, with the price to cash flow ratio at 165.40.
Repligen Corporation’s quick ratio for the period ended September 29 was 1.70, with the current ratio over the same period at 2.30. In terms of profitability, the gross margin trailing 12 months is 57.90%. The firm’s gross profit as reported stood at $391.25 million against revenue of $670.53 million.
For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 17.1% to $40.41 million, while revenue of $49.86 million was -23.39% off the previous quarter. Analysts expected RGEN to announce $0.68 per share in earnings in its latest quarter, but it posted $0.77, representing a 13.20% surprise. EBITDA for the quarter stood at more than $65.79 million. RGEN stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 627.42 million, with total debt at $418.51 million. Shareholders hold equity totaling $55.52 million.
Let’s look briefly at Repligen Corporation (RGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 54.31% to suggest the stock is trending Neutral, with historical volatility in this time period at 45.45%.
The stock’s 5-day moving average is $185.26, reflecting a -2.65% or -$4.91 change from its current price. RGEN is currently trading +4.93% above its 20-day SMA, -17.73% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +3.46% and SMA200 by+1.57%.
Stochastic %K and %D was 80.27% and 80.32% and the average true range (ATR) pointed at 9.53. The RSI (14) points at 53.97%, while the 14-day stochastic is at 69.41% with the period’s ATR at 9.39. The stock’s 9-day MACD Oscillator is pointing at 3.18 and 10.60 on the 14-day charts.
In the most recent analyst report for Repligen Corporation (NASDAQ: RGEN), Deutsche Bank launched coverage with a Hold rating. Analysts offering their rating for RGEN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate RGEN as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is RGEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $180.00 and a high of $270.00, with their median price target at $230.00. Looking at these predictions, the average price target given by analysts is for Repligen Corporation (RGEN) stock is $225.55.